Baidu
map

Hereditas:在一个中国感音神经性听力损失家庭中发现HARS2的两个新的可能致病变异

2020-12-13 AlexYang MedSci原创

HARS2的突变是Perrault综合征的遗传病因之一,具有感音神经性听力损失(SNHL)和卵巢功能障碍特征。

HARS2的突变是Perrault综合征的遗传病因之一,具有感音神经性听力损失(SNHL)和卵巢功能障碍特征。

最近,有研究人员通过靶向二代测序方法,在一个中国感音神经性听力损失家族中发现了两个新的HARS2致病变异,分别是c.349G > A(p.Asp117Asn)和c.908 T > C(p.Leu303Pro)。其中两名受影响的兄弟(13岁和11岁)表现为早期发病、快速进展的SNHL。该对兄弟没有任何内耳畸形或大肌肉动作发育迟缓。结合已有的临床报道,Perrault综合征可能潜伏在一些与HARS2突变相关的非综合征耳聋家庭中。对于散发男性以及没有POI症状的青春期前女性,仅根据临床特征对Perrault综合征进行确诊是一个挑战。

HARS2变异的生信分析

最后,研究人员指出,他们的研究结果进一步扩展了现有的HARS2变异谱和Perrault综合征表型,这将有助于HARS2突变患者的分子诊断和遗传咨询。

原始出处:

Jing Yu, Wei Jiang, Li Cao et al. Two novel likely pathogenic variants of HARS2 identified in a Chinese family with sensorineural hearing loss. Hereditas. Nov 2020

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2035476, encodeId=812820354e6dc, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Fri Jul 16 05:47:02 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306597, encodeId=49c6130659e7a, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Tue Dec 15 03:47:02 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342752, encodeId=6b861342e52ff, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Dec 15 03:47:02 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907589, encodeId=c44790e589e7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Dec 13 12:55:09 CST 2020, time=2020-12-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2035476, encodeId=812820354e6dc, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Fri Jul 16 05:47:02 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306597, encodeId=49c6130659e7a, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Tue Dec 15 03:47:02 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342752, encodeId=6b861342e52ff, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Dec 15 03:47:02 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907589, encodeId=c44790e589e7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Dec 13 12:55:09 CST 2020, time=2020-12-13, status=1, ipAttribution=)]
    2020-12-15 ysjykql
  3. [GetPortalCommentsPageByObjectIdResponse(id=2035476, encodeId=812820354e6dc, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Fri Jul 16 05:47:02 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306597, encodeId=49c6130659e7a, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Tue Dec 15 03:47:02 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342752, encodeId=6b861342e52ff, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Dec 15 03:47:02 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907589, encodeId=c44790e589e7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Dec 13 12:55:09 CST 2020, time=2020-12-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2035476, encodeId=812820354e6dc, content=<a href='/topic/show?id=d382e42956d' target=_blank style='color:#2F92EE;'>#神经性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74295, encryptionId=d382e42956d, topicName=神经性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=927d310, createdName=hywen7326, createdTime=Fri Jul 16 05:47:02 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1306597, encodeId=49c6130659e7a, content=<a href='/topic/show?id=aeb639230b7' target=_blank style='color:#2F92EE;'>#听力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39230, encryptionId=aeb639230b7, topicName=听力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Tue Dec 15 03:47:02 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342752, encodeId=6b861342e52ff, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Tue Dec 15 03:47:02 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907589, encodeId=c44790e589e7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Dec 13 12:55:09 CST 2020, time=2020-12-13, status=1, ipAttribution=)]
    2020-12-13 ms3000000449926787

    学习

    0

相关资讯

Lancet主编称西方以反华掩饰失败; 全新评论称维生素D治疗新冠?

《柳叶刀》主编直言:美国攻击中国是为掩饰其抗疫失败!

中国批准国产阿尔茨海默症早诊示踪剂进入III期临床

18F-APN-1607是国内首个申报临床的tau蛋白示踪剂产品,也是新旭医药首个在国内进入临床试验III期的一类新药药物。目前tau蛋白已被医学界认可为AD的重要生物靶点。

揭秘:印、菲、阿等争相引进,我国新冠疫苗到底强在哪里?

11月,全球很可能正式迎来第一支新冠疫苗。此时距离已知的首例新冠肺炎病例被发现,不足10个月。这一速度远超一般疫苗研发所需的8-10年时间。

Lancet Planetary Health:近30年空气污染对我国疾病、死亡、寿命的影响变化趋势

在中国,空气污染是一个重要的公共卫生问题,因为我们周围环境和家庭空气污染的水平较高。为了向我国各省采取行动提供数据信息,研究人员估算了1990年-2017年期间中国所有省份的空气污染暴露及其对死亡、疾

Gene:中国显性双侧小耳症家族中HOXA2功能缺失变异的鉴定

HOX基因是影响头部形成的重要调控基因,包括了耳朵的发育。小耳症是一种先天性的耳朵畸形,表现为外侧耳朵结构全部或者部分的缺失。到目前为止,只有4个HOXA2变异在常染色体隐性或者显性小耳症家族中报道,

BMJ Open:中国职业噪音诱导的听力损失:系统回顾与元分析

中国大多数职业人群正面临着噪声引起的听力损失(NIHL)的风险。然而,关于中国职业NIHL的文献综述数量非常有限。最近,有研究人员利用相关研究的数据分析中国人群中职业性NIHL的患病率和特征情况。

Baidu
map
Baidu
map
Baidu
map